Comparative Pharmacology
Head-to-head clinical analysis: ERTAPENEM SODIUM versus INVANZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERTAPENEM SODIUM versus INVANZ.
ERTAPENEM SODIUM vs INVANZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ertapenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death. It is a carbapenem antibiotic with broad-spectrum activity against Gram-positive and Gram-negative aerobes and anaerobes.
Ertapenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
1 g IV or IM once daily.
1 g IV or IM once daily
None Documented
None Documented
Terminal half-life: ~4 hours (range 3.5-5.3) in young adults; prolonged in renal impairment (e.g., ~7.5 hours in moderate impairment, ~13 hours in end-stage renal disease)
Terminal elimination half-life approximately 4 hours; prolonged to approximately 8 hours in mild to moderate renal impairment (CrCl 30-59 mL/min) and to 14 hours in severe renal impairment (CrCl <30 mL/min); clinical context: requires dosage adjustment in renal impairment.
Renal: ~80% unchanged in urine; fecal: ~10% as metabolites; biliary: minimal (<1%)
Renal: ~80% unchanged in urine; biliary/fecal: ~10% as unchanged drug and the open-ring metabolite; minor hepatic metabolism.
Category A/B
Category C
Carbapenem Antibiotic
Carbapenem Antibiotic